The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study.
What's New
Daily losartan was associated with significantly lower rates of paclitaxel-induced peripheral neuropathy in women with early-stage breast cancer.
Detailed Summary
A single-center, open-label, randomized controlled trial of 89 women with early-stage breast cancer receiving weekly paclitaxel found that losartan 100 mg daily was associated with a lower incidence of grade ≥2 neuropathy (33.3% vs. 86.4%, p<0.001) and delayed onset (73.3 vs. 43.8 days; HR 0.2, 95% CI: 0.11-0.35) compared to standard care alone, with no additional adverse events.
Study Population
Women with early-stage breast cancer scheduled for weekly paclitaxel chemotherapy (n=89)
This research is for informational purposes only — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.
Discussion
Loading comments...
Comments are public. Be respectful and remember: this is not medical advice. Do not share personal health information.